Once daily sustained release tablets of venlafaxine, a novel antidepressant

被引:41
作者
Makhija, SN [1 ]
Vavia, PR [1 ]
机构
[1] Univ Mumbai, Dept Chem Technol, Div Pharmaceut, Bombay 400019, Maharashtra, India
关键词
venlafaxine; matrix system; hydroxypropylmethylcellulose; cellulose acetate; Eudragit RSPO; ethylcellulose; in vivo studies;
D O I
10.1016/S0939-6411(02)00049-8
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Venlafaxine is a unique antidepressant that differs structurally from other currently available antidepressants. Sustained release tablets of venlafaxine to be taken once daily were formulated with venlafaxine hydrochloride equivalent to 75 mg of venlafaxine base. Matrix system based on swellable as well as non-swellable polymers was selected for sustaining the drug release. Different polymers viz. hydroxypropylmethylcellulose (HPMC), cellulose acetate, Eudragit RSPO, ethylcellulose etc. were studied. Combinations of non-swellable polymers with HPMC were also tried in order to get the desired sustained release profile over a period of 16 It. The effect of drug to polymer ratio on in vitro release was studied. The marketed formulation was evaluated for different parameters such as appearance, weight variation, drug content and in vitro drug release. The optimized formulation was subjected to stability studies at different temperature and humidity conditions as per ICH guidelines. These were evaluated for appearance, weight variation, thickness, hardness, friability, drug content and in vitro drug release at selected time intervals. In vivo studies were carried out for the optimized formulation in 12 healthy human volunteers and the pharmacokinetic parameters were compared with the marketed one. (C) 2002 Published by Elsevier Science B.V.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 15 条
[1]
BINDING OF ANTIDEPRESSANTS TO HUMAN BRAIN RECEPTORS - FOCUS ON NEWER GENERATION COMPOUNDS [J].
CUSACK, B ;
NELSON, A ;
RICHELSON, E .
PSYCHOPHARMACOLOGY, 1994, 114 (04) :559-565
[2]
Extension of the International Conference on Harmonization Tripartite Guideline for Stability Testing of New Drug Substances and Products to countries of climatic zones III and IV [J].
Grimm, W .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1998, 24 (04) :313-325
[3]
HASKINS J T, 1984, Society for Neuroscience Abstracts, V10, P262
[4]
A HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS DETERMINATION OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE IN BIOLOGICAL-FLUIDS [J].
HICKS, DR ;
WOLANIUK, D ;
RUSSELL, A ;
CAVANAUGH, N ;
KRAML, M .
THERAPEUTIC DRUG MONITORING, 1994, 16 (01) :100-107
[5]
ONLINE TELEMETRY - PROSPECTIVE ASSESSMENT OF ACCURACY IN AN ALL-VOLUNTEER EMERGENCY MEDICAL-SERVICE SYSTEM [J].
HOLLANDER, JE ;
DELAGI, R ;
SCIAMMARELLA, J ;
VICCELLIO, P ;
ORTIZ, J ;
HENRY, MC .
ACADEMIC EMERGENCY MEDICINE, 1995, 2 (04) :280-286
[6]
BIOCHEMICAL, NEUROPHYSIOLOGICAL, AND BEHAVIORAL-EFFECTS OF WY-45,233 AND OTHER IDENTIFIED METABOLITES OF THE ANTIDEPRESSANT VENLAFAXINE [J].
MUTH, EA ;
MOYER, JA ;
HASKINS, JT ;
ANDREE, TH ;
HUSBANDS, GEM .
DRUG DEVELOPMENT RESEARCH, 1991, 23 (02) :191-199
[7]
ANTIDEPRESSANT BIOCHEMICAL PROFILE OF THE NOVEL BICYCLIC COMPOUND WY-45,030, AN ETHYL CYCLOHEXANOL DERIVATIVE [J].
MUTH, EA ;
HASKINS, JT ;
MOYER, JA ;
HUSBANDS, GEM ;
NIELSEN, ST ;
SIGG, EB .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (24) :4493-4497
[8]
Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium [J].
Troy, SM ;
Parker, VD ;
Hicks, DR ;
Boudino, D ;
Chiang, ST .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (02) :175-181
[9]
Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers [J].
Troy, SM ;
Dilea, C ;
Martin, PT ;
Rosen, AS ;
Fruncillo, RJ ;
Chiang, ST .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1997, 58 (08) :492-503
[10]
Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine [J].
Troy, SM ;
Parker, VP ;
Hicks, DR ;
Pollack, GM ;
Chiang, ST .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (10) :954-961